Polish Selvita’s Inflammation Research used to start new Biotech in Scotland

29/07/2016 - 3 minutes

The new Biotech Nodthera will be based in Edinburgh and focus on the discovery and development of novel small molecule candidates to treat inflammation in a range of autoimmune diseases. Founded by Epidarex Capital, it will work alongside Selvita (Poland) in a series of deals worth up to €6.35M.

Selvita nodthera biotech inflammasome The technology behind Nodthera’s focus is built on work conducted by the Polish drug-discovery company, Selvita, which is headquartered in Kraków. Starting out as a CRO, Selvita now operates on a hybrid-model, also working on in-house programs.

On the other hand, Epidarex Capital is an early-stage investor which launched Nodthera on the basis of Selvita’s technology. Now Nodthera has signed 3 deals with Selvita for the commercialisation of its SEL212 program, which was originally launched with $1.1M non-dilutive funding from the EU to get to an IND stage.

The first deal was for the sale of the SEL212A program to Nodthera for around €600K (£0.5M),

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: